vs
HARVARD BIOSCIENCE INC（HBIO）与因美纳（ILMN）财务数据对比。点击上方公司名可切换其他公司
因美纳的季度营收约是HARVARD BIOSCIENCE INC的46.5倍（$1.1B vs $23.7M）。因美纳净利率更高（16.8% vs -12.0%，领先28.8%）。因美纳同比增速更快（-1.6% vs -3.3%）。因美纳自由现金流更多（$335.0M vs $-545.0K）。过去两年因美纳的营收复合增速更高（0.8% vs -1.6%）
哈佛生物科学是一家全球生命科学设备开发商、制造商与销售商，其产品主要用于支撑科研开发与药物研发工作，目前该公司在纳斯达克上市，股票交易代码为HBIO。
因美纳是总部位于美国加利福尼亚州圣迭戈的生物技术企业，成立于1998年4月，专注研发、生产及销售用于分析基因变异与生物功能的集成系统，产品及服务覆盖测序、基因分型、基因表达、蛋白质组学等领域，业务遍及全球超155个国家和地区。
HBIO vs ILMN — 直观对比
营收规模更大
ILMN
是对方的46.5倍
$23.7M
营收增速更快
ILMN
高出1.7%
-3.3%
净利率更高
ILMN
高出28.8%
-12.0%
自由现金流更多
ILMN
多$335.5M
$-545.0K
两年增速更快
ILMN
近两年复合增速
-1.6%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $23.7M | $1.1B |
| 净利润 | $-2.8M | $186.0M |
| 毛利率 | 59.7% | 65.9% |
| 营业利润率 | 7.2% | 15.8% |
| 净利率 | -12.0% | 16.8% |
| 营收同比 | -3.3% | -1.6% |
| 净利润同比 | -15916.7% | 205.7% |
| 每股收益（稀释后） | $-0.06 | $1.16 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HBIOILMN
| Q4 25 | $23.7M | — | ||
| Q3 25 | $20.6M | — | ||
| Q2 25 | $20.4M | — | ||
| Q1 25 | $21.8M | — | ||
| Q4 24 | $24.6M | $1.1B | ||
| Q3 24 | $22.0M | $1.1B | ||
| Q2 24 | $23.1M | $1.1B | ||
| Q1 24 | $24.5M | $1.1B |
净利润HBIOILMN
| Q4 25 | $-2.8M | — | ||
| Q3 25 | $-1.2M | — | ||
| Q2 25 | $-2.3M | — | ||
| Q1 25 | $-50.3M | — | ||
| Q4 24 | $18.0K | $186.0M | ||
| Q3 24 | $-4.8M | $705.0M | ||
| Q2 24 | $-2.9M | $-2.0B | ||
| Q1 24 | $-4.7M | $-126.0M |
毛利率HBIOILMN
| Q4 25 | 59.7% | — | ||
| Q3 25 | 58.4% | — | ||
| Q2 25 | 56.4% | — | ||
| Q1 25 | 56.0% | — | ||
| Q4 24 | 57.1% | 65.9% | ||
| Q3 24 | 58.1% | 69.0% | ||
| Q2 24 | 57.2% | 64.8% | ||
| Q1 24 | 60.3% | 62.0% |
营业利润率HBIOILMN
| Q4 25 | 7.2% | — | ||
| Q3 25 | 1.0% | — | ||
| Q2 25 | -4.0% | — | ||
| Q1 25 | -228.1% | — | ||
| Q4 24 | 0.0% | 15.8% | ||
| Q3 24 | -8.5% | 68.6% | ||
| Q2 24 | -9.0% | -147.2% | ||
| Q1 24 | -9.3% | -10.3% |
净利率HBIOILMN
| Q4 25 | -12.0% | — | ||
| Q3 25 | -6.0% | — | ||
| Q2 25 | -11.2% | — | ||
| Q1 25 | -231.2% | — | ||
| Q4 24 | 0.1% | 16.8% | ||
| Q3 24 | -21.9% | 65.3% | ||
| Q2 24 | -12.7% | -178.8% | ||
| Q1 24 | -19.1% | -11.7% |
每股收益（稀释后）HBIOILMN
| Q4 25 | $-0.06 | — | ||
| Q3 25 | $-0.03 | — | ||
| Q2 25 | $-0.05 | — | ||
| Q1 25 | $-1.14 | — | ||
| Q4 24 | $0.01 | $1.16 | ||
| Q3 24 | $-0.11 | $4.42 | ||
| Q2 24 | $-0.07 | $-12.48 | ||
| Q1 24 | $-0.11 | $-0.79 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $8.6M | $93.0M |
| 总债务越低越好 | $35.9M | — |
| 股东权益账面价值 | $13.7M | $2.4B |
| 总资产 | $80.1M | $6.3B |
| 负债/权益比越低杠杆越低 | 2.61× | — |
8季度趋势，按日历期对齐
现金及短期投资HBIOILMN
| Q4 25 | $8.6M | — | ||
| Q3 25 | $6.8M | — | ||
| Q2 25 | $7.4M | — | ||
| Q1 25 | $5.5M | — | ||
| Q4 24 | $4.1M | $93.0M | ||
| Q3 24 | $4.6M | $70.0M | ||
| Q2 24 | $4.0M | $74.0M | ||
| Q1 24 | $4.3M | — |
总债务HBIOILMN
| Q4 25 | $35.9M | — | ||
| Q3 25 | $34.0M | — | ||
| Q2 25 | $34.9M | — | ||
| Q1 25 | $36.4M | — | ||
| Q4 24 | $37.0M | — | ||
| Q3 24 | $34.9M | — | ||
| Q2 24 | $35.7M | — | ||
| Q1 24 | $35.6M | — |
股东权益HBIOILMN
| Q4 25 | $13.7M | — | ||
| Q3 25 | $14.1M | — | ||
| Q2 25 | $15.7M | — | ||
| Q1 25 | $14.8M | — | ||
| Q4 24 | $63.3M | $2.4B | ||
| Q3 24 | $65.3M | $2.1B | ||
| Q2 24 | $67.2M | $1.4B | ||
| Q1 24 | $68.8M | $5.7B |
总资产HBIOILMN
| Q4 25 | $80.1M | — | ||
| Q3 25 | $78.0M | — | ||
| Q2 25 | $80.1M | — | ||
| Q1 25 | $79.8M | — | ||
| Q4 24 | $126.6M | $6.3B | ||
| Q3 24 | $131.2M | $6.0B | ||
| Q2 24 | $128.9M | $6.1B | ||
| Q1 24 | $133.2M | $10.0B |
负债/权益比HBIOILMN
| Q4 25 | 2.61× | — | ||
| Q3 25 | 2.41× | — | ||
| Q2 25 | 2.22× | — | ||
| Q1 25 | 2.45× | — | ||
| Q4 24 | 0.58× | — | ||
| Q3 24 | 0.53× | — | ||
| Q2 24 | 0.53× | — | ||
| Q1 24 | 0.52× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-96.0K | $364.0M |
| 自由现金流经营现金流 - 资本支出 | $-545.0K | $335.0M |
| 自由现金流率自由现金流/营收 | -2.3% | 30.3% |
| 资本支出强度资本支出/营收 | 1.9% | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.96× |
| 过去12个月自由现金流最近4个季度 | $5.5M | $709.0M |
8季度趋势，按日历期对齐
经营现金流HBIOILMN
| Q4 25 | $-96.0K | — | ||
| Q3 25 | $1.1M | — | ||
| Q2 25 | $2.8M | — | ||
| Q1 25 | $3.0M | — | ||
| Q4 24 | $1.7M | $364.0M | ||
| Q3 24 | $-842.0K | $316.0M | ||
| Q2 24 | $-846.0K | $80.0M | ||
| Q1 24 | $1.4M | $77.0M |
自由现金流HBIOILMN
| Q4 25 | $-545.0K | — | ||
| Q3 25 | $877.0K | — | ||
| Q2 25 | $2.7M | — | ||
| Q1 25 | $2.5M | — | ||
| Q4 24 | $1.4M | $335.0M | ||
| Q3 24 | $-1.7M | $284.0M | ||
| Q2 24 | $-1.7M | $49.0M | ||
| Q1 24 | $758.0K | $41.0M |
自由现金流率HBIOILMN
| Q4 25 | -2.3% | — | ||
| Q3 25 | 4.3% | — | ||
| Q2 25 | 13.0% | — | ||
| Q1 25 | 11.4% | — | ||
| Q4 24 | 5.8% | 30.3% | ||
| Q3 24 | -7.8% | 26.3% | ||
| Q2 24 | -7.2% | 4.4% | ||
| Q1 24 | 3.1% | 3.8% |
资本支出强度HBIOILMN
| Q4 25 | 1.9% | — | ||
| Q3 25 | 1.0% | — | ||
| Q2 25 | 0.4% | — | ||
| Q1 25 | 2.4% | — | ||
| Q4 24 | 1.2% | 2.6% | ||
| Q3 24 | 4.0% | 3.0% | ||
| Q2 24 | 3.5% | 2.8% | ||
| Q1 24 | 2.6% | 3.3% |
现金转化率HBIOILMN
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 95.83× | 1.96× | ||
| Q3 24 | — | 0.45× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HBIO
| Instruments Equipment Software And Accessories | $21.6M | 91% |
| Service Maintenance And Warranty Contracts | $2.1M | 9% |
ILMN
| Sequencing | $1.0B | 91% |
| Microarray | $101.0M | 9% |
| Investee | $7.0M | 1% |
